Showing results (41-50 of 207) with videos related to
Sort By:
Pageof 21
Diabetes & Metabolism|May 8, 2010
Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivityV Preumont, M-P Hermans, S Brichard, et al.Current Medical Research and Opinion|May 21, 2010
Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i)J C Fruchart, F M Sacks, M P Hermans, et al.British Journal of Clinical Pharmacology|January 1, 1989
Focus on diastolic dysfunction: a new approach to heart failure therapyH Pouleur, C Hanet, O Gurné, et al.Journal of the American College of Cardiology|December 1, 1992
Diastolic function of the nonfilling human left ventricleW J Paulus, P J Vantrimpont, M F RousseauEuropean Journal of Cardiology|January 1, 1975
Early hemodynamic adaptations to physical training in patients with healed myocardial infarctionJ M Detry, M F Rousseau, L A BrasseurThe American Journal of Cardiology|July 1, 1991
Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure StudyH Pouleur, M F Rousseau, C Oakley, et al.European Heart Journal|April 1, 1990
Echocardiographic assessment of lack of beta 1-receptor down-regulation during prolonged therapy with xamoterolP Cheron, M Nannan, H Pouleur, et al.Diabetes & Metabolism|November 5, 2004
C677T methylene-tetrahydrofolate reductase mutation in type 2 diabetic patients with and without hyperhomocysteinaemiaM Buysschaert, J L Gala, A Bessomo, et al.Diabetes & Metabolism|April 26, 2008
Belonging to a diabetes patients' association is predictive of better metabolic controlP L Selvais, K D Amoussou-Guenou, M P HermansDiabetes & Metabolism|April 9, 2002
Clinical expression and insulin sensitivity in type 2 diabetic patients with heterozygous mutations for haemochromatosisS Van Lerberghe, M P Hermans, K Dahan, et al.Pageof 21